Sugi Predict

Sugi Predict / Compounds / SCHEMBL689790

SCHEMBL689790

SCHEMBL689790

CCOC(=O)c1c(-c2cccc(OC)c2)csc1N

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.78
▸ HSD17B10 Q99714 5/20 0.78
▸ MAPT P10636 4/20 0.78
▸ LMNA P02545 1/20 0.78
▸ MAPK1 P28482 1/20 0.67
▸ PRKCZ Q05513 11/20 0.67
▸ PRKCI P41743 3/20 0.64
▸ KCNH2 Q12809 1/20 0.64
▸ HPGD P15428 1/20 0.62
▸ MEN1 O00255 3/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ ALOX15 P16050 2/20 0.61
▸ USP2 O75604 1/20 0.61
▸ TDP1 Q9NUW8 1/20 0.59
▸ GAA P10253 1/20 0.58
▸ KEAP1 Q14145 1/20 0.58
▸ PTPN1 P18031 1/20 0.56
▸ MPI P34949 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8289403 0.88 PRKCZ (0.66) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL5322173 0.88 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL8290366 0.87 ALDH1A1 (0.64) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL689612 0.86 HSD17B10 (0.77) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL8288638 0.86 PRKCZ (0.72) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL689305 0.85 ALDH1A1 (0.70) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL8288636 0.85 ALDH1A1 (0.70) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL689196 0.85 PRKCZ (0.78) ALDH1A1HSD17B10MAPTMAPK1PRKCZ
SCHEMBL8289775 0.84 ALDH1A1 (0.69) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL689025 0.84 PRKCZ (0.73) ALDH1A1HSD17B10MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2512242-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-30 — — EP disclosed
EP-2512242-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-30 — — EP disclosed
US-9029545-B2 Thienopyridine NOX2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2015-05-12 — — US disclosed
US-9029545-B2 Thienopyridine NOX2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2015-05-12 — — US disclosed
EP-2512242-A1 NOVEL COMPOUNDS Glaxo Wellcome Manufacturing Pte Ltd (SG) 2012-10-24 — — EP disclosed
US-20120252805-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2012-10-04 — — US disclosed
US-20120252805-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2012-10-04 — — US disclosed
EP-1953148-B1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2012-02-29 — — EP disclosed
WO-2011075559-A1 NOVEL COMPOUNDS GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) 2011-06-23 — — WO disclosed
WO-2011075559-A1 NOVEL COMPOUNDS GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) 2011-06-23 — — WO disclosed
US-7449490-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2008-11-11 — — US disclosed
EP-1953148-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-08-06 — — EP disclosed
US-7101905-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-09-05 — — US disclosed
US-20060183921-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2006-08-17 — — US disclosed
US-20060183759-A1 Tissue transglutaminase inhibitors BRIGHAM AND WOMEN'S HOSPITAL, INC., THE 2006-08-17 — — US disclosed
WO-2006060702-A1 SUBSTITUED 3,4-DIHYDROTHIENO [2,3-D] PYRMIDINES AS TISSUE TRANSGLUTAMINASE INHIBITORS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2006-06-08 — — WO disclosed
WO-2005033102-A2 THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMPHORA DISCOVERY CORPORATION (US) 2005-04-14 — — WO disclosed
EP-1383463-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE King Pharmaceuticals, Inc. (US) 2004-01-28 — — EP disclosed
US-20030073733-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-04-17 — — US disclosed
WO-2002083083-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS, INC. (US) 2002-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252805-A1 NOVEL COMPOUNDS CYBB, NOX1, NOX4 ALDH1A1 734/4885HSD17B10 362/4885MAPT 1781/4885
US-20060183921-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE ALDH1A1 1591/4885HSD17B10 2648/4885MAPT 1176/4885
US-20030073733-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE ALDH1A1 1591/4885HSD17B10 2648/4885MAPT 1176/4885
US-20060183759-A1 Tissue transglutaminase inhibitors TGM2, HNMT, TPMT ALDH1A1 3116/4885HSD17B10 1221/4885MAPT 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.